ArticleClinical kidney journal2026
Early postoperative galectin-3 for risk stratification of delayed graft function after kidney transplantation.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Delayed graft function (DGF) is a major early complication after kidney transplantation. Galectin-3 (Gal3), a mediator of inflammation and fibrosis, is associated with renal injury, but its role in predicting DGF remains unclear. This study evaluated whether early postoperative Gal3 levels predict DGF and clinical outcomes. Methods: This single-center retrospective cohort study included adult kidney transplant recipients from deceased donors (January 2021-December 2022). Gal3 was measured preoperatively, at intensive care unit (ICU) admission, and at ICU discharge. The primary outcome was DGF, defined as renal replacement therapy within 7 days. A base clinical model (age, cold ischemia time, creatinine at ICU admission) was compared with a Gal3-extended model, assessed by area under the curve (AUC), Brier score, calibration, bootstrap optimism correction, and categorical net reclassification improvement. Results: Among 182 patients, 35 (19.2%) developed DGF. Gal3 at ICU admission was significantly higher in DGF patients (52.3 vs. 40.0 ng/ml, Conclusion: Gal3 measured at ICU admission was independently associated with DGF and provided modest incremental risk-stratification value. External validation is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.